Mechanism of 3-mercaptopicolinic acid inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP).

doi:10.1016/s0021-9258(17)33923-6

Paper

Mechanism of 3-mercaptopicolinic acid inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP).

Published Jan 10, 1976 · M. Jomain-Baum, V. Schramm, R. Hanson

The Journal of biological chemistry

Q1 SJR score

98

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

3-mercaptopicolinic acid inhibits gluconeogenesis from lactate in fasted rats and guinea pigs by removing a tightly bound, rapidly exchanging metal ion other than Mn2+.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Mechanism of 3-mercaptopicolinic acid inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP).

Sign up to use Study Snapshot

References

Citations

Suppression of PCK1 attenuates neuronal injury and improves post-resuscitation outcomes.

Suppressing PCK1 during CPR can improve survival rates and prognosis in mice after cardiac arrest, potentially offering a novel treatment strategy.

Biochemical, structural, and kinetic characterization of PPi‐dependent phosphoenolpyruvate carboxykinase from Propionibacterium freudenreichii

PPi-dependent phosphoenolpyruvate carboxykinase from Propionibacterium freudenreichii is a Fe2+ activated enzyme with unique kinetic properties compared to GTP- and ATP-dependent enzymes.

The phosphoenolpyruvate carboxykinase (PEPCK) inhibitor, 3-mercaptopicolinic acid (3-MPA), induces myogenic differentiation in C2C12 cells

3-MPA, a PEPCK inhibitor, induces myogenic differentiation in C2C12 cells, potentially through the inhibition of PEPCK-M.

Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M.

iPEPCK-2 is a promising anticancer drug targeting PEPCK-M, a hallmark gene product involved in tumor metabolic adaptations, without weight loss or toxicity.

3-((carboxymethyl)thio)-picolinic acid - A novel inhibitor of phosphoenolpyruvate carboxykinase.

CMP is a selective inhibitor of phosphoenolpyruvate carboxykinase, occupying both the OAA/PEP binding sites simultaneously, offering potential for creating additional selective inhibitors of PEPCK.